JAZZ has been the topic of several other reports. Piper Jaffray Companies set a $202.00 price objective on Jazz Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, May 28th. BMO Capital Markets set a $208.00 price objective on Jazz Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, July 3rd. ValuEngine downgraded Valero Energy from a hold rating to a sell rating in a research report on Wednesday, May 8th. Oppenheimer set a $176.00 price objective on Jazz Pharmaceuticals and gave the company a buy rating in a research report on Monday, July 8th. Finally, Mizuho set a $148.00 price objective on Jazz Pharmaceuticals and gave the company a hold rating in a research report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. Jazz Pharmaceuticals has an average rating of Buy and an average target price of $179.41.
Shares of Jazz Pharmaceuticals stock opened at $136.62 on Thursday. The firm has a 50-day simple moving average of $134.77. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $181.46. The stock has a market capitalization of $7.74 billion, a P/E ratio of 11.16, a price-to-earnings-growth ratio of 1.14 and a beta of 1.15. The company has a quick ratio of 3.01, a current ratio of 3.15 and a debt-to-equity ratio of 0.63.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The business had revenue of $508.19 million for the quarter, compared to the consensus estimate of $466.55 million. During the same period in the previous year, the business earned $2.98 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. Analysts forecast that Jazz Pharmaceuticals will post 13.23 earnings per share for the current year.
Several large investors have recently bought and sold shares of JAZZ. Norges Bank bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $82,304,000. JPMorgan Chase & Co. increased its stake in Jazz Pharmaceuticals by 16.7% during the first quarter. JPMorgan Chase & Co. now owns 2,262,159 shares of the specialty pharmaceutical company’s stock worth $323,376,000 after acquiring an additional 324,080 shares during the last quarter. Wedge Capital Management L L P NC bought a new stake in Jazz Pharmaceuticals during the first quarter worth approximately $40,947,000. LSV Asset Management increased its stake in Jazz Pharmaceuticals by 31.0% during the first quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock worth $143,185,000 after acquiring an additional 237,190 shares during the last quarter. Finally, Clark Capital Management Group Inc. increased its stake in Jazz Pharmaceuticals by 620.5% during the first quarter. Clark Capital Management Group Inc. now owns 227,533 shares of the specialty pharmaceutical company’s stock worth $32,526,000 after acquiring an additional 195,951 shares during the last quarter. Institutional investors own 89.81% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.